Pharmafile Logo

Cuttsy+Cuttsy awarded Gold EcoVadis sustainability rating

December 11, 2024 | ESG, Sustainability 

Cuttsy+Cuttsy proudly announces their Gold Medal achievement from EcoVadis for 2024, placing them among the top 5% of companies assessed and within the 97th percentile, a testament to their unwavering commitment to sustainability and advanced ESG practices.

EcoVadis Gold Medal

Following the assessment of the 2024 EcoVadis submission, Cuttsy+Cuttsy is excited to announce they have been awarded a Gold Medal on their sustainability scorecard. This places the agency among the top 5% of companies assessed by EcoVadis in the past 12 months.

Not only this, but Cuttsy+Cuttsy’s high score placed them in the 97th percentile of all companies assessed in 2024, making them just shy of a platinum rating (the top possible rating within the EcoVadis scoring system).

EcoVadis, a globally trusted provider of business sustainability ratings with a network of over 130,000 rated companies, works with organisations of all sizes to measure sustainability performance. The platform offers detailed insights on environmental, social and governance (ESG) risk management, compliance and corporate sustainability goals.

Caroline Benson, Co-Founder, says, “We’re delighted with our ‘gold’ rating, a big advancement from last year’s ‘silver’, that showcases our dedication to continuous improvement across all our ESG practices.”

Mathew Cutts adds, “This achievement reinforces our pledge to uphold and exceed the highest standards in sustainability across our operations and value chain.”

This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

New report now available: Integrating ‘patient first’ into medicine development

A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map...

The digital prescription – enhancing the patient experience with technology

We explore how digital health innovations are revolutionising patient care by enhancing accessibility, personalisation, and engagement, promising a more connected and empowered patient experience.

Compliance — a driving force for influencing public perceptions of the pharma industry?

How does compliance play into public perceptions of pharma and why is it important for improving public opinion?

Another year, another B!

Louise Jones, Cuttsy+Cuttsy's Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.

Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director

Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.

Clinical trial considerations: Why supporting HCPs matters…

When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.

Clinical trial considerations: Why diversity matters…

Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...

Clinical trial considerations: Why digital matters…

Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.

Clinical trials explained: Why imagery matters…

Recruiting patients for clinical trials is one of pharma's greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the...

Clinical trials explained: Why health literacy matters…

Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...